Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment

Bibliography

• GILKS C, CROWLEY S, EKPINI R et al.: The WHO public-health approach to antiretroviral treatment against HIV in resource poor settings. Lancet (2006) 368:505-510.
   PubMed Web of Science ®Google Scholar
• HAMMER SM, SAAG MS, SCHECHTER M et al.: Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 296:827-843.
   PubMed Web of Science ®Google Scholar
• IRIBARREN JA, LABARGA P, RUBIO R et al.: Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected adults. Enferm. Infecc. Microbiol. Clin. (2004) 22:564-642.
   PubMed Web of Science ®Google Scholar
• CALMY A, PINOGES L, SZUMILIN E et al.: Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS (2006) 20:1163-1169.
   PubMed Web of Science ®Google Scholar
• FERRADINI L, JEANNIN A, PINOGUES L et al.: Scaling up highly active antiretroviral therapy in the district of Malawi: an effectiveness assessment. Lancet (2006) 367:1335-1342.
   PubMed Web of Science ®Google Scholar
• VAN LETH F, PHANUPHAK P, RUXRUNGTHAM K et al.: Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet (2004) 363(9417):1253-1263.
   PubMed Web of Science ®Google Scholar
• SPRUANCE S, PAVIA A, MELLORS J et al.: Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine experienced patients in a randomized, double-blind, controlled trial. Bristol-Myers Stavudine 019 Study Group. Ann. Intern. Med. (1997) 126(5):355-363.
   PubMed Web of Science ®Google Scholar
• SQUIRES KE, GULICK R, TEBAS P et al.: A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). AIDS (2000) 14(11):1591-1600.
   PubMed Web of Science ®Google Scholar
• WALMSLEY S, BERNSTEIN B, KING M et al.: Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N. Engl. J. Med. (2002) 346:2039-2046.
   PubMed Web of Science ®Google Scholar
• BARTLETT J, FATH M, DEMASI R et al.: An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS (2006) 20:2051-2064.
   PubMed Web of Science ®Google Scholar
• MOCROFT A, PHILLIPS A, LEDERGERBER B et al.: Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viraemia. AIDS (2006) 20:1141-1150.
   PubMed Web of Science ®Google Scholar
• GALLANT J, STASZEWSKI S, POZNIAK A et al.: Efficacy and safety of tenofovir DF versus stavudine in combination therapy in antiretroviral naïve patients. JAMA (2004) 292:191-201
   PubMed Web of Science ®Google Scholar
• BROWNE M, MAYER K, CHAFEE S et al.: 2´,3´-didehydro-3´-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex. J. Inf. Dis. (1993) 167:21-29.
   PubMed Web of Science ®Google Scholar
• PETERSEN E, RAMIREZ-RONDA C, HARDY D et al.: Dose-related activity of stavudine in patients infected with human immunodeficiency virus. J. Inf. Dis. (1995) 171(Suppl. 1):S131-S139.
   PubMed Web of Science ®Google Scholar
• CARR A, MILLER J, LAW M et al.: A syndrome of lipoatrophy, lactic acidaemia and liver disfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS (2000) 14:F25-F32.
   PubMed Web of Science ®Google Scholar
• FALC V, CRESPO M, RIBERA E: Lactic acidosis related to nucleoside therapy in HIV infection. Expert Opin. Pharmacother. (2003) 4:1321-1329.
   PubMedGoogle Scholar
• POLLARD R, PETERSON D, HARDY D et al.: Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm3. J. Acq. Immuno Sydr. (1999) 22:39-45.
   PubMed Web of Science ®Google Scholar
• ANDERSON R, DUNKLE L, SMALDONE L et al.: Design and implementation of the stavudine parallel track programme. Comparison of safety and efficacy of two doses of stavudine in a simple trial in the US parallel track programme. J. Inf. Dis. (1995) 171:118-122.
   Google Scholar
• RUXRUNGTHAM K, KROON E, UNGSEDHAPAND C et al.: A randomised, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naïve, HIV-infected Thai patients. AIDS (2000) 14:1375-1382.
   PubMed Web of Science ®Google Scholar
• SIANGPHOE U, SRIKAEW S, WAIWAVARAVUTH C et al.: Efficacy and safety of half dose compared to full dose stavudine (d4T) and zidovudine (AZT) in combination with didanosine (ddI) in Thai HIV-infected patients: 96-week results of ACTT002/ARV065 study. World AIDS Conference. Bangkok, Thailand (July 2004) Abstr. WePeB5952.
   Google Scholar
• RIBERA E, PARADINERO J, DOMINGO P et al.: A randomized study comparing the efficacy and tolerability of low-dose versus standard-dose stavudine in antiretroviral-naïve patients (ETOX study). 3rd International Conference on AIDS Pathogenesis. Rio de Janiero, Brazil (July 2005) Abstr. TuPe2.4c10.
   Google Scholar
• MILINKOVIC A, LOPEZ S, VIDAL S et al.: A randomized open study comparing the effect of reducing stavudine dose versus switching to tenofovir on mitochondrial function, metabolic parameters, and subcutaneous fat in hiv-infected patients receiving antiretroviral therapy containing stavudine. 12th Conference on Retroviruses and Opportunistic Infections. Boston, USA (February 2005) Abstr. 857.
   Google Scholar
• SANCHEZ-CONDE M, SORIANO V, GONZALEZ-LAHOZ J: Dose reduction in stavudine from 40 to 30 mg bid provides similar virological and immunological benefit. XV International AIDS Conference (2004) Poster exhibition. Abstr. TuPeB4459.
   Google Scholar
• KOEGL C, WOLF E, POSTEL N et al.: Low dose stavudine: as effective as standard dose but less side effects. 9th European AIDS Conference (EACS). Warsaw (25 October 2003) Abstr. 9.8/5.
   Google Scholar
• URBINA A, JIBILIAN A, NIBBE Y et al.: Evaluation of viral efficacy and safety of a reduced dose of stavudine (d4T): the PHOENIX study. European AIDS Treatment conference. Dublin, Ireland, (November 2005) Abstr.
   Google Scholar
• SHALIT P, FARRELL P, MCCARTHY M: Long-term efficacy of a protease inhibitor sparing, NRTI limiting antiretroviral regimen with nevirapine, lamivudine and reduced dose stavudine dosage. HIV Clin. Trials (2004) 51:62-64.
   Google Scholar
• AIT MOHAND H, BONMARCHAND M, GUIGET M et al.: Evaluation of viral efficacy and safety of a reduced dose of stavudine (d4T): the PHOENIX study. European AIDS Treatment Conference. Dublin, Ireland, (November 2005) Abstr.
   Google Scholar
• HANVANICH M, PRASANTHAI V, RIENGCHAN P et al.: Reduction of d4T dosage improves lipoatrophy without virologic failure. Antiviral Therapy (2003) 8(Suppl. 1): S392 Abstr. 749.
   Google Scholar
• DELPIERRE C, CUZIN L, ALVAREZ M et al.: Lowering stavudine dosages does not compromise anti-viral efficacy in HIV-1 infected patients. IAS Conference on Pathogenesis Rio de Janiero, Brazil (July 2005) Abstr.
   Google Scholar
• ARMITAGE P, BERRY G: Statistical Methods in Medical Research, 3rd edn. Blackwell Scientific Publications, Oxford, UK (1994).
   Google Scholar
• CROSS J, LEE H, WESTELINK A et al.: Postmarketing drug dosage changes of 499 FDA approved new molecular entities. Pharmaco Drug Saf.ety (2002) 11:439-446.
   PubMed Web of Science ®Google Scholar
• MOYLE G, SABIN C, CARTLEDGE J et al.: A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipodystrophy. AIDS (2006) 20:2043-2050.
   PubMed Web of Science ®Google Scholar
• BOULASSEL M, MORALES R, MURPHY T et al.: Gender and long-term metabolic toxicities from antiretroviral therapy in HIV-1 infected patients. J. Med. Virol. (2006) 78:1158-1163.
   PubMed Web of Science ®Google Scholar
• CALMY A, PINOGUES L, SZUMILIN E et al.: Scaling up highly active antiretroviral therapy in the district of Malawi: an effectiveness assessment. Lancet (2006) 367:1335-1342.
   PubMedGoogle Scholar
• FERRADINI L, JEANNIN A, PINOGUES L et al.: Scaling up highly active antiretroviral therapy in the district of Malawi: an effectiveness assessment. Lancet (2006) 367:1335-1342.
   Google Scholar